AstraZeneca Stock News

Tempus AI (NASDAQ:TEM) said on Wednesday it has signed multi-year strategic collaborations with AstraZeneca (AZN.L) and Pathos AI to co-develop what it called the largest multimodal foundation model in oncology, sending its shares up more than 15% in morning trading. The deals, which include $200 million in data licensing and model development fees to Tempus, will leverage the company's vast re...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced multi-year, strategic collaborations with AstraZeneca (LSE/STO/Nasdaq: AZN) and Pathos AI, Inc., in which the companies will work together to build a multimodal foundation model in oncology which can be used to gather biological...

AstraZeneca Chief Executive Officer Pascal Soriot said on Wednesday that Europe has stepped up its defence spending and now must protect its health sovereignty amid a shifting world order.

AstraZeneca has rejoined the main U.S. drug lobby group, roughly two years after leaving it, the Pharmaceutical Research and Manufacturers of America (PhRMA) said on Tuesday.

Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector.

AstraZeneca PLC (LSE:AZN) reported notable progress in ongoing trials of patients with metastatic breast cancer using a combination of drugs, Enhertu and pertuzumab. Enhertu, jointly developed by the Anglo-Swedish drug company and Japan's Daiichi Sankyo, is being combined with Roche's pertuzumab in the DESTINY-Breast09 Phase III trials, and showed a statistically significant and clinically mean...

Die US-Investmentbank Goldman Sachs hat die Einstufung für Astrazeneca GB0009895292 mit einem Kursziel von 15318 Pence auf "Buy" belassen.

The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.